Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Will Manufacture siRNAs for Calando

NEW YORK (GenomeWeb News) - Agilent Technologies will manufacture siRNAs for Calando, Calando said today.
Agilent will manufacture the active siRNA component for Calando’s targeted siRNA anti-cancer therapeutic, CALAA01. Agilent will also provide Investigational New Drug-enabling services such as pharmacokinetic and toxicity studies and cGMP production.
Calando is a majority owned subsidiary of Arrowhead Research Formed. Founded in 2005, it creates, develops and sells technologies for the therapeutic use of RNAi.
Financial details of the agreement were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.